Lenalidomide alone and in combination for chronic lymphocytic leukemia.

about

Chronic lymphocytic leukaemia--the role of the microenvironment pathogenesis and therapy.Efficacy of lenalidomide in relapsed/refractory chronic lymphocytic leukemia patient: a systematic review and meta-analysis.

P2860

Q38101683-F9FA2A2F-C458-41A7-8E26-B53CAAD52AFF Q38872460-556925EE-9749-4551-9C32-D49502E4AE11

P2860

Lenalidomide alone and in combination for chronic lymphocytic leukemia.

Item

http://www.wikidata.org/entity/Q38068736

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Lenalidomide alone and in combination for chronic lymphocytic leukemia.

@en

type

Item

label

Lenalidomide alone and in combination for chronic lymphocytic leukemia.

@en

prefLabel

Lenalidomide alone and in combination for chronic lymphocytic leukemia.

@en

P1476

Lenalidomide alone and in combination for chronic lymphocytic leukemia.

@en

P2093

Christine I Chen

http://www.w3.org/2001/XMLSchema#string

P2860

Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study.

A phase I study of lenalidomide in combination with fludarabine and rituximab in previously untreated CLL/SLL.

Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia.

Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathway.

Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia

Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia.

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial.

Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide.

The role of phosphatidylinositol 3-kinase-δ in the immunomodulatory effects of lenalidomide in chronic lymphocytic leukemia.

Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia.

P2888

s11899-012-0146-x

P304

7-13

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11899-012-0146-X

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2013-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1026225680

http://www.w3.org/2001/XMLSchema#string

P698

23254517

http://www.w3.org/2001/XMLSchema#string

P921

lymphocyte

Lenalidomide alone and in combination for chronic lymphocytic leukemia.

about

P2860

P2860

Lenalidomide alone and in combination for chronic lymphocytic leukemia.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P6179

P698

P921

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P6179

P698

P921